Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Cesar Homero Gutiérrez-AguirreDalila Marisol Alvarado-NavarroAlain Palomares-LealGerardo Mejía-JaramilloRosario Salazar-RiojasAndrés Gómez-De LeónPerla Rocío Colunga-PedrazaGuillermo Sotomayor-DuqueJosé Carlos Jaime-PérezOlga Graciela Cantú-RodríguezLuz Del Carmen Tarín-ArzagaJuan Antonio Flores-JiménezDavid Gómez-AlmaguerPublished in: Transfusion (2019)
RD-plerixafor is an effective, safe, and affordable strategy to ensure adequate PBSC mobilization in patients with MM or lymphoma who undergo ASCT.